About Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited (AETL), incorporated in 1989 as Advanced Biochemicals Private Limited, is headquartered in Thane, Maharashtra. Over more than three decades, the Company has emerged as India’s largest and one of the world’s leading enzyme companies, specialising in research, development and manufacturing of enzymes and probiotics. AETL’s portfolio exceeds 400 proprietary enzyme formulations derived from over 65 indigenous enzymes, serving industries spanning human nutrition, animal nutrition, pharmaceuticals, food processing, textiles, biofuels and environmental applications.

The Company’s growth has been supported by a series of strategic acquisitions and expansions, including JC Biotech (India), evoxx technologies GmbH (Germany), and SciTech Specialities (India). Subsidiaries extend AETL’s presence across the Americas, Europe, and Asia, with facilities in India, the United States, and Germany. In 2024, the Company also established Starya Labs in California for independent testing of enzymes and probiotics.

Advanced Enzyme Technologies Limited Milestone

Key milestones include commissioning its first fermentation facility at Sinnar in 1994, floating its IPO in 2016, acquiring 100% stake in evoxx in 2017, and commissioning a 350 kW solar plant in 2025. These moves reflect the Company’s balance of innovation, sustainability, and global expansion.

Advanced Enzyme Technologies Limited’s Business Segments

AETL operates through four principal verticals:

• Human Nutrition – 64% of revenue. This is the Company’s largest vertical, comprising enzymes and probiotics for pharmaceuticals and nutraceuticals.

• Industrial Bioprocessing – 16% of revenue. This includes food enzymes for baking, brewing, fruit processing, starch, biofuels and textile applications.

• Animal Nutrition – 12% of revenue, driven by science-backed formulations improving gut health, feed conversion and immunity in cattle and poultry.

• Specialised Manufacturing – 8% of revenue, including effervescent-based products through SciTech Specialities.

Geographically, international markets contribute the majority share, with significant presence in the Americas, Asia (excluding India), and Europe.

Advanced Enzyme Technologies Limited Key Management

• Mr. Vasant Rathi – Chairman and Non-Executive Director

• Mr. Beni Prasad Rauka – Group CFO and Director (subsidiaries)

• Mr. Dipak Roda – Sr. Vice President, Marketing & Business Development

• Mr. Sanjay Basantani – Company Secretary & Head-Legal

• Mr. Harshad Doshi – CFO & COO (U.S. subsidiaries)

• Ms. Martina Doering – MD/Head of Business Development, evoxx technologies GmbH, Germany

• Dr. Michael Puls – MD/Head of R&D, evoxx technologies GmbH, Germany
  advance

Latest Updates on Advanced Enzyme Technologies Limited

In FY 2024–25, AETL reported consolidated revenue of Rs 6,369 million, a 2% year-on-year growth. Human Nutrition remained the mainstay, while Animal Nutrition grew 12% and specialised manufacturing rose 30%. Subsidiaries such as SciTech Specialities recorded strong performance. Investments in R&D touched Rs 248 million (4% of revenue), supporting 15–16 new molecules under development.

The Company commissioned a 350 kW solar power plant to further its clean energy commitment and received the “Zero Hazardous Discharge Certificate 3.0”. It also advanced a new R&D facility at Nashik, spanning 1,00,000 square feet, with capex of Rs 469 million. Starya Labs in the U.S. was set up as an independent enzyme and probiotic testing facility to address regulatory compliance needs.